月旦知識庫
  1. 熱門:
 
首頁 臺灣期刊   法律   公行政治   醫學   財經   社會學   教育   其他 大陸期刊   核心   非核心 DOI文章
本站僅提供期刊文獻檢索。【月旦知識庫】是否收錄該篇全文,敬請【登入】查詢為準。
最新【購點活動】
篇名
雙磷酸鹽類藥物使用對骨鬆骨折病人死亡率的影響-健保資料庫分析
並列篇名
Bisphosphonate and Mortality in Patients with Osteoporotic Fracture: An Analysis based on National Health Insurance Research Database
作者 許育煊 (Yu-Hsuan Hsu)李佳純 (Chia-Chun Li)梁富文 (Fu-Wen Liang)張尹凡 (Yin-Fan Chang)徐之昇 (Jason C. Hsu)吳至行 (Chih-Hsing Wu)
中文摘要

目的:使用骨質疏鬆藥物可降低骨鬆骨折後死亡風險,而台灣相對缺乏本土的巨資料研究,尤其是雙磷酸鹽類藥物的研究更是不足。本研究旨在探討骨鬆骨折後有無使用雙磷酸鹽類藥物對死亡率之影響。

方法:本研究納入2009至2017年全民健康保險資料庫之門診有骨質疏鬆症診斷且有住院骨折住院診斷新發個案,串連死因統計檔,分析有無使用雙磷酸鹽類藥物對於全死因死亡的風險。

結果:本研究總樣本為149,288人,存活者平均追蹤人年為4.96人年,死亡者為3.15人年。相較於無使用雙磷酸鹽類藥物者,使用雙磷酸鹽類藥物的死亡風險比為0.97 (95% CI 0.95-0.99)。而單獨使用口服alendronate/risedronate的死亡風險比為1.01 (95% CI 0.99-1.03),針劑ibandronate為0.87 (95% CI 0.81-0.93),針劑zoledronic acid則為0.74 (95% CI 0.70-0.78)。在髖骨骨折或脊椎骨折的次分析皆有相似結果。

結論:本研究發現骨鬆骨折個案使用雙磷酸鹽類藥物者之整體死亡風險顯著降低,尤其是針劑藥物。此研究結果應可供臨床實務及公共政策之參考。

 

英文摘要

Purpose: While pharmacological intervention does help reduce the risk of total mortality induced by osteoporotic fracture, few studies have been conducted to examine the impact of specific drugs, especially bisphosphonates, on osteoporotic fractures in Taiwan. Therefore, the study aimed to analyze the relationship between the use of bisphosphonates for osteoporotic fractures and resulting mortality.

Methods: The National Health Insurance Research Database (NHIRD), together with the Cause of Death Data, provided by Health and Welfare Data Science Center was consulted for analysis on subjects hospitalized for osteoporotic fracture from 2009 to 2017 to study the connection between the use of bisphosphonates and mortality among patients with osteoporotic fracture.

Results: A total of 149,288 valid participants were enrolled, and the mean follow-up personyears of the survivor and death were respectively 4.96 and 3.15. Compared with those who used no bisphosphonates, the mortality hazard ratio was 0.97 (95% confidence interval, CI 0.95-0.99)for patients receiving bisphosphonates, 1.01 (95% CI 0.99-1.03) for oral alendronate/risedronate, 0.87 (95% CI 0.81-0.93) for ibandronate by injection, and 0.74 (95% CI 0.70-0.78) for zoledronic acid in total fractures. Consistent results were found in subgroup-analysis of hip fractures or spine fractures.

Conclusion: Use of bisphosphonates, especially through injection, appears to be significantly associated with reduced mortality in patients with osteoporotic fractures. The result of this study should be considered in clinical practice and public policy.

 

起訖頁 199-213
關鍵詞 bisphosphonatefracturesmortalityosteoporosis
刊名 台灣家庭醫學雜誌  
期數 202109 (31:3期)
出版單位 台灣家庭醫學醫學會
該期刊-上一篇 台灣成年民眾使用傳統與民俗療法及其相關因素的探討
該期刊-下一篇 台灣南部某縣市醫師對分級醫療六大策略之認同度及滿意度調查
 

新書閱讀



最新講座


優惠活動




讀者服務專線:+886-2-23756688 傳真:+886-2-23318496
地址:臺北市館前路28 號 7 樓 客服信箱
Copyright © 元照出版 All rights reserved. 版權所有,禁止轉貼節錄